STOCKHOLM - April 29, 2020 - Fredrik Palm, CEO of ContextVision, has on April
28, 2020 purchased 1000 shares in ContextVision AB at an average price of NOK
120 per share. After the transaction, Mr Palm holds a total of 2500 shares in
ContextVision AB.

Monsun AS, controlled by Magne Jordanger, member of the board of ContextVision,
has on April 28, 2020 purchased 2000 shares in ContextVision AB at an average
price of NOK 120 per share. After the transaction, Monsun AS holds a total of
2 300 000 shares in ContextVision AB which is maximum holding without obligation
to launch a bid according to Swedish law.

For further information, please contact ContextVision's CEO, Fredrik Palm, at
+46 76 870 25 43 or visit www.contextvision.com (http://www.contextvision.com/).

                                      ###

About ContextVision

ContextVision is a medical technology software company specialized in image
analysis and artificial intelligence. As the global market leader within image
enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-
ray and MRI equipment around the world.

Our expertise is to develop powerful software products, based on proprietary
technology and artificial intelligence for image-based applications. Our
cutting-edge technology helps clinicians accurately interpret medical images, a
crucial foundation for better diagnosis and treatment.

ContextVision is now entering the fast-growing digital pathology market. We are
re-investing significantly in our product portfolio of decision support tools
and we are dedicated to becoming a leading resource for pathologists to
radically develop cancer diagnosis and improve patient care.

The company, established in 1983, is based in Sweden with local representation
in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock
Exchange under the ticker COV.



This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act